相关实验视频

Updated: May 15, 2025

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

对抗肺结核DprE1抑制剂的图书法测量和可视化分析

Qingqing Wang¹, Huixiao Fu², Yining Zhang³

¹College of Pharmacy, Guizhou University of Traditional Chinese Medicine/National Engineering Technology Research Center for Miao Medicine/Guizhou Engineering Technology Research Center for Processing and Preparation of Traditional Chinese Medicine and Ethnic Medicine, Guiyang, People's Republic of China.

Drug design, development and therapy

|April 8, 2025

概括

这项文献计量研究揭示了Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 作为结核病研究中的一个关键目标. 新兴趋势集中在新型抗结核病剂的DprE1抑制剂上.

科学领域:

* 结核病研究研究
* 药物的发现和开发.
* 分子生物学和生物化学

背景情况:

* 结核病 (TB) 构成了全球重大卫生挑战,多抗药性 (MDR-TB) 和广泛抗药性 (XDR-TB) 菌株的增加加剧了这一问题.
* Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 是维护菌根菌细胞壁的完整性和活力的关键酶.
*迫切需要针对结核病的新型治疗策略,需要全面了解关键分子标,如DprE1.1.

研究的目的:

* 在结核病 (TB) 背景下对Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 的研究进行文献计和视觉分析.
*绘制知识框架,确定关键贡献者,并概述DprE1和结核病领域的研究趋势.
*为未来的研究和开发针对DprE1.1.的新型抗结核病剂提供数据驱动的基础.

主要方法:

*使用Web of Science核心集合数据库进行了系统的文献搜索.
*使用了包括VOSviewer和CiteSpace在内的图书识别分析和可视化工具.
*分析包括期刊,国家,机构,作者,参考文献和关键词,以绘制研究格局.

主要成果:

* 总共分析了184个出版物,累计引用3405次.
* 结核病中DprE1的年度出版量显示出显著的增长趋势.
*确定的主要研究领域包括"Mtb"",DprE1"和"抑制剂",这表明重点是开发针对DprE1的抗结核药物.

结论:

* Decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1) 仍然是抗结核病研究的一个核心焦点.
* 本文献分析为DprE1相关结核病研究的现状和未来方向提供了宝贵的见解.
*这些发现可以指导开发针对DprE1.1的新型抗结核病剂.

关键词:

在CiteSpace中使用CiteSpace.DprE1 抑制剂的使用这就是R-bibliometrix.在VOSviewer中使用VOSviewer.药物目标是药物目标.结核病是一种肺结核病.

更多相关视频

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...